Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05907954 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Study sites: 24 to 18v24 Show 1 more changeShow less
    • Study sites: 24 to 18
  2. Enrollment target: 82 to 160 Primary completion date: Jan 31, 2026 to Apr 30, 2027 · Primary endpoints: 3 to 4 · Study sites: 25 to 24 · 4 morev23 Show 7 more changesShow less
    • Primary completion date: Jan 31, 2026 to Apr 30, 2027
    • Primary endpoints: 3 to 4
    • Study sites: 25 to 24
    • Completion date: Jan 31, 2029 to Apr 30, 2030
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints: 4 to 5
    • Study description expanded, about 8 words

    See this version in full on ClinicalTrials.gov ↗

  3. Re-verified, no change to tracked fieldsv22
  4. Site details revised at 5 of 25 sitesv21
  5. Site details revised at 1 of 25 sitesv20
Show 18 earlier versionsHide 18 earlier versions
  1. Study sites revised (25)v19 See this version in full on ClinicalTrials.gov ↗
  2. Site details revised at 1 of 25 sitesv18
  3. Site contacts updated at 1 of 25 sitesv17
  4. Study sites: 23 to 25v16
  5. Study sites revised (23)v15 See this version in full on ClinicalTrials.gov ↗
  6. Study sites: 22 to 23v14
  7. Study sites: 21 to 22v13
  8. Study sites: 12 to 21v12
  9. Site details revised at 1 of 12 sitesv11
  10. Study sites: 11 to 12v10
  11. Re-verified, no change to tracked fieldsv9
  12. Study sites revised (11)v8 See this version in full on ClinicalTrials.gov ↗
  13. Study sites revised (11)v7 See this version in full on ClinicalTrials.gov ↗
  14. Study sites revised (11)v6 See this version in full on ClinicalTrials.gov ↗
  15. Study sites: 12 to 11v5
  16. Study sites: 9 to 12v4
  17. Study sites: 3 to 9v3
  18. Study sites: 1 to 3 Start date changed from estimate of Jun 2023 to Jul 3, 2023v2 Show 1 more changeShow less
    • Start date changed from estimate of Jun 2023 to Jul 3, 2023
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
IDEAYA Biosciences
11 trials monitored
See all monitored trials
Melanoma
1,026 trials monitored
See 48 trials at risk
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Trial Details
NCT Number NCT05907954
Lead Sponsor IDEAYA Biosciences
Conditions Uveal Melanoma
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov